Identifying potential therapeutic drug targets and validating their suitability is a complex process involving numerous experimental platforms, including DNA sequence analysis. Since its introduction in 2005 next-generation sequencing (NGS) has fundamentally altered genomics research. Large knowledge-gaining experiments are in progress that were financially unjustifiable or even impossible five years ago. These include metagenomics to compare different disease states or patient variablility, genome sequencing of model and pathogenic species or ELT compound library screening techniques.
NGS is now successfully utilised by biopharmaceutical companies from the earliest stages of drug discovery to provide detailed genomic data and clinical applications are now emerging. These range from investigating the molecular basis of drug resistance and planning antimicrobial regimens, to vaccine development and disease diagnostics. In the rapidly growing field of personalised medicine, eight percent of medicines now have a biomarker or stratified element as compared to just a few percent five years ago.
As sequencing costs continue to fall, the future will see even faster identification of responders and non-responders, benefiting patients, prescribers and payors.
Production for the event is now underway. To discuss the progam or speak at the meeting please contact
For sponsorship and exhibition opportunities please contact
Why should you attend this event?
Join us for two days of insights and case studies from leading experts and industry executives, enabling you to:
Hear keynote addresses from:
Our expert speaker line-up also includes:
Who should attend?
Presidents, Chief Executive Officers, Chief Scientific Officers, Chief Technology Officers, Chief Operating Officers, Vice Presidents, Directors, Professors, Heads, Program Managers and Team Leaders in:
© 2013 Bioscreening.com